Page 68 - product-manual
P. 68

TM/MC  TM/MC
                                          PHARMACOLOGICAL ACTIVITIES - TOXICOLOGY - DRUG INTERACTIONS






                    Phyllanthus emblica


                    Toxicity for Fructus Phyllanthi has not been documented in dogs and cats when administered orally in therapeutic
                TOXICOLOGY  weight in mice. The standardized aqueous extract of Fructus Phyllanthi, with an LD  >5,000 mg/kg of body
                    doses. Single dose subcutaneous of 50% ethanol extract of Fructus Phyllanthi showed LD  of 4.8 g/kg of body
                                                                                                50
                                                                                             50
                    weight was found to be non-toxic through acute exposure in rats (Jaijoy et al., 2010).


                    Equivalent toxic dose in 20 kg dog:   96 g SC of Fructus Phyllanthi 50% ethanol extract.
                    Equivalent toxic dose in 5 kg cat:    24 g SC of Fructus Phyllanthi 50% ethanol extract.



                      DRUG     Validated interactions studies do not exist for Fructus Phyllanthi preparations. Clinical interactions
              INTERACTIONS     with  other  drugs  have  not  been  reported.  However,  extracts  of  Fructus  Phyllanthi  has  shown
                               synergistic effects with doxorubicin and cisplatin in vitro (Pinmai et al., 2008).





            Ledebouriella divaricata  (Siler)


            In traditional Chinese medicine Radix Ledebouriellae Divaricatae is the herb of choice for body
            aches and pain (Chen & Chen, 2004). The extract of Radix Ledebouriellae Divaricatae exhibits
            anti-proliferative, antioxidant and anti-inflammatory activities (Taj & Cheung, 2007) and these
            activities are attributed to the chemical constituents prim-O-glucosylcimifugin and 4’-O-β-D-
            glucosyl-5-O-methylvisamminol (Xue et al. 2000). Administration of Radix Ledebouriellae
            Divaricatae suppressed the development of type II collagen-induced arthritis in animal models
            which may support the traditional use of Radix Ledebouriellae Divaricatae in treating human
            rheumatoid arthritis (Wang et al., 1999).



                    Toxicity for Radix Ledebouriellae Divaricatae has not been documented in dogs and cats when administered
               TOXICOLOGY  to mice is 37.18 ± 8.36 g/kg of body weight (Li, 2002).
                    orally in therapeutic doses. The oral LD  for aqueous extracts of Radix Ledebouriellae Divaricatae administered
                                                     50

                    Equivalent toxic dose in 20 kg dog:   745 g PO of Radix Ledebouriellae Divaricatae aqueous extract.
                    Equivalent toxic dose in 5 kg cat:
                                                     20 g PO of Radix Ledebouriellae Divaricatae aqueous extract.



                       DRUG    Validated  interactions  studies  do  not  exist  for  Radix  Ledebouriellae  Divaricatae  preparations.
              INTERACTIONS     Clinical interactions with other drugs have not been reported.











                                                                                                 Articulare-VM TM       |  7
   63   64   65   66   67   68   69   70   71   72   73